Fastest cited synthesis for verified US clinicians
40/50
2nd of 5
| Corpus & currency | Citation fidelity | Retrieval precision | Point-of-care fit | Access & eligibility |
|---|---|---|---|---|
| 9/10 | 9/10 | 8/10 | 7/10 | 7/10 |
- Best for
- Verified US clinicians who want a fast, well-cited synthesis of recent published evidence at no cost, with content partnerships spanning the New England Journal of Medicine and the JAMA Network.
- Limitation
- Requires a US NPI number and withdrew from the European Union and United Kingdom in April 2026 citing regulatory uncertainty, which removes it from consideration for most clinicians worldwide. It shows no reasoning path and offers no public developer API.
- Price
- Free, funded by pharmaceutical advertising
Dimension-by-dimension rubric criteria for clinical evidence retrieval tools
- Corpus & currency9/10
Category high: 10/10
Size and breadth of the indexed literature, coverage of guidelines alongside primary papers, refresh cadence, and whether rarer clinical questions are represented rather than only common presentations.
- Citation fidelity9/10
Category high: 10/10
Whether every citation resolves to a real, retrievable source; whether the cited source actually supports the sentence it is attached to; and whether the strength of that evidence is graded rather than asserted.
- Retrieval precision8/10
Category high: 10/10
Whether the tool returns the evidence that answers the question asked, including negative and equivocal findings, and whether you can audit why a given source was selected over the alternatives.
- Point-of-care fit7/10
Category high: 8/10
Whether retrieval fits the ninety seconds actually available during an encounter: latency, mobile access, in-chart reach through SMART on FHIR or Infobutton, and offline availability.
- Access & eligibility7/10
Category high: 10/10
Published pricing, free tier, credential gating such as a US NPI requirement, regional availability, and language coverage.


